argenx Revenue and Competitors
Estimated Revenue & Valuation
- argenx's estimated annual revenue is currently $510.1M per year.
- argenx's estimated revenue per employee is $464,977
- argenx's total funding is $2B.
- argenx's current valuation is $15.2B. (January 2022)
Employee Data
- argenx has 1097 Employees.
- argenx grew their employee count by 31% last year.
argenx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 32 | -26% | N/A | N/A |
#2 | $510.1M | 1097 | 31% | $2B | N/A |
#3 | $13.6M | 88 | 44% | N/A | N/A |
#4 | $12.2M | 79 | 0% | N/A | N/A |
#5 | $28.7M | 185 | 5% | N/A | N/A |
#6 | $35.2M | 227 | 8% | N/A | N/A |
#7 | $4M | 26 | -10% | N/A | N/A |
#8 | $10.9M | 70 | 23% | N/A | N/A |
#9 | $10.4M | 67 | 24% | N/A | N/A |
#10 | $6.2M | 40 | 29% | N/A | N/A |
What Is argenx?
argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey. argenx is listed on the Euronext Brussels exchange under the symbol ARGX.
keywords:N/A
$2B
Total Funding
1097
Number of Employees
$510.1M
Revenue (est)
31%
Employee Growth %
$15.2B
Valuation
N/A
Accelerator
argenx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director, Peer to Peer Marketing | Reveal Email/Phone |
2 | Clinical Editor | Reveal Email/Phone |
3 | Rare Disease Account Manager | Reveal Email/Phone |
4 | Safety Risk Management Lead | Reveal Email/Phone |
5 | Head Thought Leader Liaisons | Reveal Email/Phone |
6 | Sr. National Account Director | Reveal Email/Phone |
7 | Territory Business Manager | Reveal Email/Phone |
8 | Market Development Director | Reveal Email/Phone |
9 | Director Biostatistics | Reveal Email/Phone |
10 | Head Neuromuscular US Medical Affairs | Reveal Email/Phone |
argenx News
argenx logo Shares of argenx SE (NASDAQ:ARGX Get Rating) have earned an average rating of Buy from the nineteen analysts that are...
Breda, the Netherlands argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with...
June 16 (Reuters) - An experimental drug developed by argenx SE led to improvements in daily activities, including chewing and swallowing, in patients suffering from a muscle-weakening autoimmune disease, according to data published in the Lancet Neurology medical journal on Wednesday. The late ...